Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD0328 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD0328 administration during fasting condition |
| 2 | EXPERIMENTAL | AZD0328 administration after food intake |
| Name | Type | Description |
|---|---|---|
| AZD0328 | DRUG | Oral capsule, single dose |
| Placebo | DRUG | Administered orally as a solution once per day on day 1, and then day 3 through to day 14. |
Inclusion Criteria: * Healthy male Caucasian subjects. * Clinically normal physical findings, laboratory values, vital signs and resting ECG as judged by the investigator. * Signed informed consent form Exclusion Criteria: * History of clinically significant cardio or cerebrovascular, pulmonary, ...
Top 20 of 24 competitors
AZD0328 is an investigational small molecule being studied for use in Alzheimer's disease and in healthy volunteers. It has been evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics. The drug is being developed by AstraZeneca PLC and is not yet approved.
AZD0328 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company has sponsored Phase 1 clinical trials of this investigational small molecule in healthy volunteers and in subjects with Alzheimer's disease.
AZD0328 is in Phase 1 clinical development. It has completed three Phase 1 trials, with no active trials currently ongoing. The drug is investigational and has not been approved by regulatory authorities. Its development status reflects early-stage testing in humans.
AZD0328 has completed three Phase 1 clinical trials: NCT00687141, which studied safety and tolerability in elderly healthy subjects in Sweden; NCT00738959, which assessed safety and pharmacokinetics in Caucasian and Japanese male subjects in the United Kingdom; and NCT00752830, which evaluated the effect of food on pharmacokinetics in Sweden.
AZD0328 is not FDA approved. It is an investigational drug that has completed Phase 1 clinical trials, which are early-stage studies focused on safety and tolerability. The drug remains in clinical development and has not received marketing approval for any indication.